Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CV Incidence in Women Receiving Endocrine Therapy

JAMA Oncol; ePub 2016 Apr 21; Haque, Shi, et al

Women with breast cancer taking an aromatase inhibitor did not have more serious cardiovascular events than those using tamoxifen, according to a retrospective cohort study involving more than 13,000 individuals.

Investigators compared cardiovascular disease incidence in those receiving various endocrine therapies. Among the results:

• There were ~3,700 cardiovascular events.

• Those using aromatase inhibitors had a similar risk of cardiac ischemia and stroke as tamoxifen-only users.

• Those using aromatase inhibitors-only or sequentially after tamoxifen had a 26% higher risk of experiencing dysrhythmia, valvular dysfunction, and pericarditis.

• Tamoxifen and nonhormone users had an 18% higher risk of such.

Citation: Haque R, Shi J, Schottinger J, et al. Cardiovascular disease after aromatase inhibitor use. [Published online ahead of print April 21, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.0429.